Chapter 29. Pharmacological Prevention of Type 2 Diabetes

  1. Dr Jean-Marie Ekoé Professor of Medicine Faculty of Medicine member recipient principal investigator co-investigator Chairman2,
  2. Dr Marian Rewers principal investigator Core director Program Chair Chair3,
  3. Rhys Williams Dean of Medicine Professor of Clinical Epidemiology chair Vice President Editor-in-Chief member visiting consultant4 and
  4. Paul Zimmet Director Hon. Professor Officer5
  1. André J. Scheen

Published Online: 11 SEP 2008

DOI: 10.1002/9780470779750.ch29

The Epidemiology of Diabetes Mellitus, Second Edition

The Epidemiology of Diabetes Mellitus, Second Edition

How to Cite

Scheen, A. J. (2008) Pharmacological Prevention of Type 2 Diabetes, in The Epidemiology of Diabetes Mellitus, Second Edition (eds J.-M. Ekoé, M. Rewers, R. Williams and P. Zimmet), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470779750.ch29

Editor Information

  1. 2

    Endocrinologie, Métabolisme et Nutrition, Centre de Recherche du CHUM, Montreal, Canada

  2. 3

    Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA

  3. 4

    Clinical Epidemiology at the School of Medicine, University of Swansea, Swansea, UK

  4. 5

    International Diabetes Institute Caulfield, Victoria, Australia

Author Information

  1. Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman, University of Liège, Liège, Belgium

Publication History

  1. Published Online: 11 SEP 2008
  2. Published Print: 19 SEP 2008

ISBN Information

Print ISBN: 9780470017272

Online ISBN: 9780470779750



  • type 2 diabetes mellitus (T2DM);
  • pediatric population - primary prevention;
  • type 2 diabetes - pharmacological prevention;
  • Troglitazone Prevention of Diabetes (TRIPOD) study;
  • glucose and lipid metabolism;
  • HOMA model insulin resistance assessment;
  • population burden of diabetes reduction


This chapter contains sections titled:

  • Introduction

  • Prevention by Glucose-lowering Agents

  • Prevention by Antiobesity Agents

  • Prevention by Lipid-Lowering Agents

  • Effects of RAAS Inhibition on Development of Diabetes

  • Prevention by Various Drugs

  • Conclusion

  • Acknowledgments

  • References